Copyright © Inderes 2011 - present. All rights reserved.

Herantis Pharma

1.635

 

EUR

 

-1.21 %

Corporate customer

HRTIS

First North Finland

Biotechnology & Pharmaceuticals

Health Care

4,213 following
Compare
-1.21%
+34.02%
+15.96%
+0.93%
+3.81%
+4.47%
-25.9%
-77.82%
-83.77%

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Read more
Market cap
32.96M EUR
Turnover
22.1K EUR
P/E (adj.) (24e)
-6.27
EV/EBIT (adj.) (24e)
-6.28
P/B (24e)
156.97
EV/S (24e)
3,300.32
Dividend yield-% (24e)
-
Coverage
Recommendation
Accumulate
Target price
2.20 EUR
Updated
23.08.2024
Disclaimer
Latest research

Latest analysis report

Released: 23.08.2024

Latest extensive report

Released: 25.06.2024

Financial calendar
6.3
2025

Annual report '24

24.4
2025

General meeting '24

21.8
2025

Interim report Q2'25

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.